2026-04-17T20:12:19Zhttps://recercat.cat/oai/request

oai:recercat.cat:10459.1/683262024-12-05T22:48:28Zcom_2072_3622col_2072_479130

00925njm 22002777a 4500 dc López Cano, Carolina author Gutiérrez Carrasquilla, Liliana author Sánchez Peña, Enric author González, Jessica author Yeramian Hakim, Andree author Martí, Raquel author Hernández García, Marta author Cao, Gonzalo author Ribelles, Mercè author Gómez Arbonés, Javier author Barril, Silvia author Barbé Illa, Ferran author Hernández, Cristina author Simó, Rafael author Lecube Torelló, Albert author 2020-03-24T12:38:25Z 2020-03-24T12:38:25Z 2019 Introduction: Many studies on the impact of type 2 diabetes mellitus (T2DM) on sleep breathing have shown a higher prevalence and severity of sleep apnea-hypopnea syndrome (SAHS) in those with T2DM. Moreover, an increased activity of the sympathetic nervous system has been described in both pathologies. This cross-sectional study aimed to assess sympathetic activity in patients with T2DM, and to investigate the relationship between sympathetic activity and polysomnographic parameters. Materials and Methods: Thirty-six patients with T2DM without known clinical macrovascularnorpulmonarydiseaseand11controlsunderwentrespiratorypolygraphy, and their cardiac variability and 24-h urine total metanephrines were measured. Results: SAHS was highly prevalent with a mean apnea-hypopnea index (AHI) in the range of moderate SAHS. In patients with T2DM, the nocturnal concentration of total metanephrines in urine were higher than diurnal levels [247.0 (120.0–1375.0) vs. 210.0 (92.0–670.0), p = 0.039]. The nocturnal total metanephrine concentration was positively and significantly associatedwith the percentage of sleeping time spent with oxygen saturation <90%(CT90). In the entire population and in subjects with T2DM, the multivariate regression analysis showed a direct interaction between the nocturnal concentration of urine metanephrines and the CT90. Conclusion: These findings suggest that the increase in sympathetic activity previously described in patients with T2DM could be mediated through nocturnal breathing disturbances. The diagnosis and treatment of SAHS may influence sympathetic activity disorders and may contribute to an improvement in T2DM and cardiovascular risk. This study was supported by grants from the Instituto de Salud Carlos III (Fondo de Investigación Sanitaria, PI12/00803 and PI15/00260), European Union (European Regional Development Fund, Fondo Europeo de Desarrollo Regional, Una manera de hacer Europa), the Fundación Sociedad Española Endocrinología y Nutrición, and Menarini Spain S.A. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. http://hdl.handle.net/10459.1/68326 Type 2 diabetes Sympathetic hyperactivity Sleep apnea-hypopnea syndrome Sleep breathing Cardiovascular risk Sympathetic Hyperactivity and Sleep Disorders in Individuals With Type 2 Diabetes